Try a new search

Format these results:

Searched for:

in-biosketch:true

person:charvl01

Total Results:

186


COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center

Parrotta, Erica; Kister, Ilya; Charvet, Leigh; Sammarco, Carrie; Saha, Valerie; Charlson, Robert Erik; Howard, Jonathan; Gutman, Josef Maxwell; Gottesman, Malcolm; Abou-Fayssal, Nada; Wolintz, Robyn; Keilson, Marshall; Fernandez-Carbonell, Cristina; Krupp, Lauren B; Zhovtis Ryerson, Lana
OBJECTIVE:To report outcomes on patients with multiple sclerosis (MS) and related disorders with coronavirus disease 2019 (COVID-19) illness. METHODS:From March 16 to April 30, 2020, patients with MS or related disorders at NYU Langone MS Comprehensive Care Center were identified with laboratory-confirmed or suspected COVID-19. The diagnosis was established using a standardized questionnaire or by review of in-patient hospital records. RESULTS:We identified 76 patients (55 with relapsing MS, of which 9 had pediatric onset; 17 with progressive MS; and 4 with related disorders). Thirty-seven underwent PCR testing and were confirmed positive. Of the entire group, 64 (84%) patients were on disease-modifying therapy (DMT) including anti-CD20 therapies (n = 34, 44.7%) and sphingosine-1-phosphate receptor modulators (n = 10, 13.5%). The most common COVID-19 symptoms were fever and cough, but 21.1% of patients had neurologic symptom recrudescence preceding or coinciding with the infection. A total of 18 (23.7%) were hospitalized; 8 (10.5%) had COVID-19 critical illness or related death. Features more common among those hospitalized or with critical illness or death were older age, presence of comorbidities, progressive disease, and a nonambulatory status. No DMT class was associated with an increased risk of hospitalization or fatal outcome. CONCLUSIONS:Most patients with MS with COVID-19 do not require hospitalization despite being on DMTs. Factors associated with critical illness were similar to the general at-risk patient population. DMT use did not emerge as a predictor of poor COVID-19 outcome in this preliminary sample.
PMID: 32646885
ISSN: 2332-7812
CID: 4518282

Functional Connectivity and Structural Disruption in the Default-Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis

Fuchs, Tom A; Ziccardi, Stefano; Benedict, Ralph H B; Bartnik, Alexander; Kuceyeski, Amy; Charvet, Leigh E; Oship, Devon; Weinstock-Guttman, Bianca; Wojcik, Curtis; Hojnacki, David; Kolb, Channa; Escobar, Jose; Campbell, Rebecca; Tran, Hoan Duc; Bergsland, Niels; Jakimovski, Dejan; Zivadinov, Robert; Dwyer, Michael G
BACKGROUND AND PURPOSE/OBJECTIVE:Efficacy of restorative cognitive rehabilitation can be predicted from baseline patient factors. In addition, patient profiles of functional connectivity are associated with cognitive reserve and moderate the structure-cognition relationship in people with multiple sclerosis (PwMS). Such interactions may help predict which PwMS will benefit most from cognitive rehabilitation. Our objective was to determine whether patient response to restorative cognitive rehabilitation is predictable from baseline structural network disruption and whether this relationship is moderated by functional connectivity. METHODS:For this single-arm repeated measures study, we recruited 25 PwMS for a 12-week program. Following magnetic resonance imaging, participants were tested using the Symbol Digit Modalities Test (SDMT) pre- and postrehabilitation. Baseline patterns of structural and functional connectivity were characterized relative to healthy controls. RESULTS:= .385, P = .017, Interaction β = -.415). CONCLUSION/CONCLUSIONS:Patient response to restorative cognitive rehabilitation is predictable from the interaction between structural network disruption and functional connectivity in the default-mode network. This effect may be related to cognitive reserve.
PMID: 32391981
ISSN: 1552-6569
CID: 4430992

Guidelines for TMS/tES clinical services and research through the COVID-19 pandemic

Bikson, Marom; Hanlon, Colleen A; Woods, Adam J; Gillick, Bernadette T; Charvet, Leigh; Lamm, Claus; Madeo, Graziella; Holczer, Adrienn; Almeida, Jorge; Antal, Andrea; Ay, Mohammad Reza; Baeken, Chris; Blumberger, Daniel M; Campanella, Salvatore; Camprodon, Joan A; Christiansen, Lasse; Loo, Colleen; Crinion, Jennifer T; Fitzgerald, Paul; Gallimberti, Luigi; Ghobadi-Azbari, Peyman; Ghodratitoostani, Iman; Grabner, Roland H; Hartwigsen, Gesa; Hirata, Akimasa; Kirton, Adam; Knotkova, Helena; Krupitsky, Evgeny; Marangolo, Paola; Nakamura-Palacios, Ester M; Potok, Weronika; Praharaj, Samir K; Ruff, Christian C; Schlaug, Gottfried; Siebner, Hartwig R; Stagg, Charlotte J; Thielscher, Axel; Wenderoth, Nicole; Yuan, Ti-Fei; Zhang, Xiaochu; Ekhtiari, Hamed
BACKGROUND:The COVID-19 pandemic has broadly disrupted biomedical treatment and research including non-invasive brain stimulation (NIBS). Moreover, the rapid onset of societal disruption and evolving regulatory restrictions may not have allowed for systematic planning of how clinical and research work may continue throughout the pandemic or be restarted as restrictions are abated. The urgency to provide and develop NIBS as an intervention for diverse neurological and mental health indications, and as a catalyst of fundamental brain research, is not dampened by the parallel efforts to address the most life-threatening aspects of COVID-19; rather in many cases the need for NIBS is heightened including the potential to mitigate mental health consequences related to COVID-19. OBJECTIVE:To facilitate the re-establishment of access to NIBS clinical services and research operations during the current COVID-19 pandemic and possible future outbreaks, we develop and discuss a framework for balancing the importance of NIBS operations with safety considerations, while addressing the needs of all stakeholders. We focus on Transcranial Magnetic Stimulation (TMS) and low intensity transcranial Electrical Stimulation (tES) - including transcranial Direct Current Stimulation (tDCS) and transcranial Alternating Current Stimulation (tACS). METHODS:The present consensus paper provides guidelines and good practices for managing and reopening NIBS clinics and laboratories through the immediate and ongoing stages of COVID-19. The document reflects the analysis of experts with domain-relevant expertise spanning NIBS technology, clinical services, and basic and clinical research - with an international perspective. We outline regulatory aspects, human resources, NIBS optimization, as well as accommodations for specific demographics. RESULTS:A model based on three phases (early COVID-19 impact, current practices, and future preparation) with an 11-step checklist (spanning removing or streamlining in-person protocols, incorporating telemedicine, and addressing COVID-19-associated adverse events) is proposed. Recommendations on implementing social distancing and sterilization of NIBS related equipment, specific considerations of COVID-19 positive populations including mental health comorbidities, as well as considerations regarding regulatory and human resource in the era of COVID-19 are outlined. We discuss COVID-19 considerations specifically for clinical (sub-)populations including pediatric, stroke, addiction, and the elderly. Numerous case-examples across the world are described. CONCLUSION/CONCLUSIONS:There is an evident, and in cases urgent, need to maintain NIBS operations through the COVID-19 pandemic, including anticipating future pandemic waves and addressing effects of COVID-19 on brain and mind. The proposed robust and structured strategy aims to address the current and anticipated future challenges while maintaining scientific rigor and managing risk.
PMCID:7217075
PMID: 32413554
ISSN: 1876-4754
CID: 4464542

Supervised transcranial direct current stimulation (tDCS) at home: A guide for clinical research and practice

Charvet, Leigh E; Shaw, Michael T; Bikson, Marom; Woods, Adam J; Knotkova, Helena
BACKGROUND:Transcranial direct current stimulation (tDCS) is a method of noninvasive neuromodulation and potential therapeutic tool to improve functioning and relieve symptoms across a range of central and peripheral nervous system conditions. Evidence suggests that the effects of tDCS are cumulative with consecutive daily applications needed to achieve clinically meaningful effects. Therefore, there is growing interest in delivering tDCS away from the clinic or research facility, usually at home. OBJECTIVE:To provide a comprehensive guide to operationalize safe and responsible use of tDCS in home settings for both investigative and clinical use. METHODS:Providing treatment at home can improve access and compliance by decreasing the burden of time and travel for patients and their caregivers, as well as to reach those in remote locations and/or living with more advanced disabilities. RESULTS:To date, methodological approaches for at-home tDCS delivery have varied. After implementing the first basic guidelines for at-home tDCS in clinical trials, this work describes a comprehensive guide for facilitating safe and responsible use of tDCS in home settings enabling access for repeated administration over time. CONCLUSION/CONCLUSIONS:These guidelines provide a reference and standard for practice when employing the use of tDCS outside of the clinic setting.
PMID: 32289698
ISSN: 1876-4754
CID: 4383422

Delivering Transcranial Direct Current Stimulation Away From Clinic: Remotely Supervised tDCS

Shaw, Michael; Pilloni, Giuseppina; Charvet, Leigh
INTRODUCTION/BACKGROUND:To demonstrate the broad utility of the remotely supervised transcranial direct current stimulation (RS-tDCS) protocol developed to deliver at-home rehabilitation for individuals with multiple sclerosis (MS). METHODS:Stimulation delivered with the RS-tDCS protocol and paired with adaptive cognitive training was delivered to three different study groups of MS patients to determine the feasibility and tolerability of the protocol. The three studies each used consecutively increasing amounts of stimulation amperage (1.5, 2.0, and 2.5 mA, respectively) and session numbers (10, 20, and 40 sessions, respectively). RESULTS:High feasibility and tolerability of the stimulation were observed for n = 99 participants across three tDCS pilot studies. CONCLUSIONS:RS-tDCS is feasible and tolerable for MS participants. The RS-tDCS protocol can be used to reach those in locations without clinic access and be paired with training or rehabilitation in locations away from the clinic. This protocol could be used to deliver tDCS paired with training or rehabilitation activities remotely to service members and veterans.
PMID: 32074357
ISSN: 1930-613x
CID: 4313222

Telerehabilitation for Neurological Disability with Remotely Supervised Transcranial Direct Current Stimulation (RS-tDCS) [Meeting Abstract]

Lee, Kelly; Ro, Amy; Lustberg, Matthew; Shaw, Michael; Khan, Nabil; Best, Pamela; Malik, Martin; Links, Jon; George, Allan; Datta, Abhishek; Bikson, Marom; Sherman, Kathleen; Krupp, Lauren; Charvet, Leigh
ISI:000536058003026
ISSN: 0028-3878
CID: 4561302

Transcranial Direct Current Stimulation (tDCS) can Reduce Fatigue and Improve Sleep Quality in Multiple Sclerosis [Meeting Abstract]

Pilloni, Giuseppina; Choi, Claire; Shaw, Michael; Krupp, Lauren; Charvet, Leigh
ISI:000536058006075
ISSN: 0028-3878
CID: 4561612

Early Neuropsychological Markers of Cognitive Involvement in Multiple Sclerosis [Meeting Abstract]

Eilam-Stock, Tehila; Shaw, Michael; Krupp, Lauren; Charvet, Leigh
ISI:000536058006262
ISSN: 0028-3878
CID: 4561652

Gait and Functional Mobility in Multiple Sclerosis: Immediate Effects of Transcranial Direct Current Stimulation (tDCS) Paired With Aerobic Exercise

Pilloni, Giuseppina; Choi, Claire; Coghe, Giancarlo; Cocco, Eleonora; Krupp, Lauren B; Pau, Massimiliano; Charvet, Leigh E
Walking impairments are a debilitating feature of multiple sclerosis (MS) because of the direct interference with daily activity. The management of motor symptoms in those with MS remains a therapeutic challenge. Transcranial direct current stimulation (tDCS) is a type of non-invasive brain stimulation that is emerging as a promising rehabilitative tool but requires further characterization to determine its optimal therapeutic use. In this randomized, sham-controlled proof-of-concept study, we tested the immediate effects of a single tDCS session on walking and functional mobility in those with MS. Seventeen participants with MS completed one 20-min session of aerobic exercise, randomly assigned to be paired with either active (2.5 mA, n = 9) or sham (n = 8) tDCS over the primary motor cortex (M1). The groups (active vs. sham) were matched according to gender (50% vs. 60% F), age (52.1 ± 12.85 vs. 54.2 ± 8.5 years), and level of neurological disability (median Expanded Disability Status Scale score 5.5 vs. 5). Gait speed on the 10-m walk test and the Timed Up and Go (TUG) time were measured by a wearable inertial sensor immediately before and following the 20-min session, with changes compared between conditions and time. There were no significant differences in gait speed or TUG time changes following the session in the full sample or between the active vs. sham groups. These findings suggest that a single session of anodal tDCS over M1 is not sufficient to affect walking and functional mobility in those with MS. Instead, behavioral motor response of tDCS is likely to be cumulative, and the effects of multiple tDCS sessions require further study. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT03658668.
PMCID:7214839
PMID: 32431658
ISSN: 1664-2295
CID: 4444282

Neuroimaging Indicates Response to Transcranial Direct Current Stimulation Treatments in Multiple Sclerosis [Meeting Abstract]

Masters, Lillian Walton; Muccio, Marco; He, Peidong; Choi, Claire; Datta, Abhishek; Bikson, Marom; Krupp, Lauren; Ge, Yulin; Charvet, Leigh
ISI:000536058003264
ISSN: 0028-3878
CID: 4561372